Group 1 - The core point of the announcement is that shareholders of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. have reduced their holdings, triggering a change in equity that touches the 1% threshold [1][3]. - The shareholders involved in the equity change include Zhuji Gaotejia Ruian Investment Partnership, Chongqing Gaotejia Ruian Equity Investment Fund Partnership, Hangzhou Gaotejia Ruihai Investment Partnership, Hangzhou Ruihong Investment Partnership, and director Wang Haijiao [3]. - From December 1 to December 30, 2025, the shareholders collectively reduced their holdings by 685,772 shares, which is 0.73% of the total share capital, decreasing their total holdings from 6,292,662 shares to 5,606,890 shares, representing a change from 6.73% to 5.99% of the total share capital [3]. Group 2 - This equity change is part of a previously disclosed reduction plan by the shareholders and does not trigger a mandatory tender offer [3]. - The equity change will not result in a change of the company's controlling shareholder or actual controller [3]. - The company will continue to monitor the shareholders' compliance with the reduction plan and will ensure timely disclosure of relevant information to investors [3].

Group 1 - The company Anbiping (688393.SH) announced that it received a notification letter from shareholders including Zhuzhou Gaotejia Ruian Investment Partnership and its concerted parties [1] - From December 1, 2025, to December 30, 2025, the aforementioned shareholders plan to reduce their holdings by a total of 685,800 shares, accounting for 0.73% of the company's total share capital [1] - Following this equity change, the total number of shares held by Zhuzhou Gaotejia and its concerted parties will decrease from 6,292,662 shares to 5,606,890 shares, reducing their ownership percentage from 6.73% to 5.99% [1]

证券代码：688393 证券简称：安必平 公告编号：2025-055 广州安必平医药科技股份有限公司 关于合计持股 5%以上股东权益变动触及 1%刻度的 提示性公告 诸暨高特佳睿安投资合伙企业（有限合伙）及其一致行动人重庆高特 佳睿安股权投资基金合伙企业（有限合伙）、杭州高特佳睿海投资合伙企业 （有限合伙）、杭州睿泓投资合伙企业（有限合伙）、董事王海蛟先生保证 向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | 其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | | 一致行动人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | | □ | 控股股东/实控人 | | | 王海蛟 | □ | 控股股东/实控人的一致 | □ ...

Group 1 - The company announced the resignation of two senior executives, Mr. Deng Zhefeng and Mr. Liang Zongseng, due to personal reasons, and they will no longer hold any positions within the company after their resignation [2][3][4] - The company held its 11th meeting of the 4th Board of Directors on December 29, 2025, where it approved the proposal to nominate Mr. Sun Hua as a non-independent director candidate, pending approval from the shareholders' meeting [5][3] - The resignations of Mr. Deng and Mr. Liang do not affect the legal number of board members and will not impact the normal operations of the board [4] Group 2 - Mr. Sun Hua, born in 1973, has a Master's degree in International Business Management from Peking University and has held various senior positions in the industry, including roles at Xiwantuo Hearing Technology and Wuhan Kanglu Biotechnology [7][8] - As of the announcement date, Mr. Sun does not hold any shares in the company and has no related party relationships with major shareholders or other executives [8] - The company expressed gratitude for the contributions made by Mr. Deng and Mr. Liang during their tenure [4]

（编辑 任世碧） 证券日报网讯 12月29日，安必平发布公告称，公司董事、副总经理邓喆锋先生因个人原因，申请辞去 董事、副总经理职务，辞任后将不再担任公司任何职务。公司副总经理梁宗胜先生因个人原因申请辞去 副总经理职务，辞任后将不再担任公司任何职务。公司于2025年12月29日召开第四届董事会第十一次会 议，审议通过了《关于补选公司非独立董事的议案》，同意提名孙华先生为公司非独立董事候选人，任 期自公司股东会审议通过之日起至公司第四届董事会任期届满之日止。 ...

Core Viewpoint - The recent research meeting revealed that the National Healthcare Security Administration's new guidelines will impact the company's business, particularly in digital pathology and AI-assisted diagnostics, which are expected to enhance efficiency and create new revenue opportunities. Group 1: Regulatory Impact - The new guidelines from the National Healthcare Security Administration include a reduction policy for digital slices and diagnostic reports not provided, with a deduction of 5 yuan per slice, capped at 15 yuan for multiple slices [1][3] - The company is in the process of registering its cervical cytology AI Class III certification, which will allow for billing in AI-assisted diagnostics [1][3] - An additional charge for pathology specimens diagnosed within 24 hours has been introduced, which AI can help achieve by improving diagnostic efficiency [1][3] Group 2: AI Product Development - The company's AI product testing has shown a significant reduction in diagnosis time from 218 seconds per slice to 30 seconds per slice, with clinical results published in "Nature Communications" [2][9] - The AI's sensitivity for primary pathologists has improved from 0.717 to 0.858, demonstrating the effectiveness of the company's AI solutions [2][9] Group 3: Market Strategy and Sales Model - The company is exploring a sales model that includes increasing reagent sales through AI empowerment and selling software with annual usage fees to hospitals [6][7] - The integration of AI into the pricing structure of pathology diagnostics is expected to facilitate negotiations with local healthcare and pricing departments [6][7] Group 4: Equipment and Collaboration - The company offers a comprehensive solution that includes reagents, equipment, and scanners, with over 300 medical institutions collaborating on scanner usage by mid-2025 [4][5] - The transition from traditional to digital pathology in lower-tier hospitals is anticipated to drive demand for digital slice scanners [1][3] Group 5: Future AI Developments - The company has multiple projects in the immunohistochemistry AI space and has acquired a manufacturer of fluorescent scanners for FISH applications, with plans to begin certification by the end of 2026 [10]

证券代码：688393 证券简称：安必平 公告编号：2025-053 广州安必平医药科技股份有限公司 关于董事、高级管理人员辞任暨补选非独立董事的公告 一、 董事、高级管理人员离任的情况 | | | 邓喆锋先生、梁宗胜先生辞任未导致公司董事会成员人数低于法定人数，不会 影响公司董事会的正常运行，已做好离任交接工作，其职务变动不会对公司正常经 营活动产生不利影响。公司及董事会对邓喆锋先生、梁宗胜先生在任职期间为公司 发展所作出的贡献表示衷心感谢！ 邓喆锋先生和梁宗胜先生是公司 2022 年限制性股票激励计划的激励对象，截至 本公告披露日，其分别持有公司股份 9,825 股、12,272 股。邓喆锋先生和梁宗胜先 生将继续遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 《上市公司股东减持股份管理暂行办法》《上海证券交易所科创板股票上市规则》 等相关法律法规。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 广州安必平医药科技股份有限公司（以下简称"公司"）董事、副总经理邓 喆锋先生因个人原因， ...

证券代码：688393 证券简称：安必平 公告编号：2025-054 广州安必平医药科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 1 月 14 日 14 点 00 分 召开地点：广州市黄埔区科信街 2 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 14 日 至2026 年 1 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2026年1月14日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票 ...

Group 1 - The core viewpoint of the news is that Anbiping's stock has shown fluctuations in price and trading volume, with a notable increase of 38.00% year-to-date, despite recent declines over the past 20 and 60 days [1][2] - As of December 25, Anbiping's stock price reached 23.75 yuan per share, with a market capitalization of 2.22 billion yuan and a trading volume of 26.80 million yuan [1] - The company has experienced a net outflow of 3.14 million yuan in principal funds, with significant selling pressure observed [1] Group 2 - Anbiping operates in the medical and biological industry, specifically in the medical device sector focusing on in vitro diagnostics [2] - For the period from January to September 2025, Anbiping reported a revenue of 253 million yuan, a year-on-year decrease of 28.29%, and a net profit attributable to shareholders of -10.77 million yuan, a decline of 136.34% [2] - The company has distributed a total of 87.80 million yuan in dividends since its A-share listing, with 36.46 million yuan distributed over the past three years [3]

安必平首次公开发行股票募集资金总额为7.13亿元，扣除发行费用后，募集资金净额为6.40亿元。 安必平最终募集资金净额较原计划多2.66亿元。安必平于2020年8月14日发布的招股说明书显示，该公 司计划募集资金3.74亿元，分别用于研发生产基地建设项目、营销服务网络升级建设项目。 安必平首次公开发行股票的发行费用为7332.49万元，其中，保荐及承销费用5719.62万元。 (责任编辑：徐自立) 中国经济网北京12月24日讯 安必平(688393.SH)今日收报23.26元，跌幅1.44%。目前该股处于破 发状态。 安必平于2020年8月20日在上交所科创板上市，发行数量为2334万股，发行价格30.56元/股，保荐 机构为民生证券（现为国联民生证券股份有限公司），保荐代表人为何尔璇、杨芳。 安必平于上市首日盘中创下股价最高点74.00元，为该股上市以来最高价。 ...